Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
  • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/136—Screening for pharmacological compounds
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/158—Expression markers

Definitions

• the present disclosure relates to methods for diagnosing a
• neurodegenerative condition such as Alzheimer's disease, using a stimulus-elicited gene expression profile.
• AD Alzheimer's disease
• AD Alzheimer's disease destroys brain cells, causing memory loss and problems with thinking and behavior that decrease quality of life. While AD has no known cure, treatments for symptoms can improve the quality of life of the millions of people suffering from AD, and that of their families.
• An early diagnosis of AD gives the patient time to make choices that maximize qualify of life and to plan for the future, reduces anxiety about unknown problems, and provides a better chance for the patient benefiting from treatment.
• AD Alzheimer's disease
• Figure 1 shows the expression levei ( icroarray data) of tumor necrosis factor receptor superfamily, member 19 (TNFRSF-19) gene in fibroblast cells from subjects with AD (ieft bar) and in fibroblast cells age-averaged control subjects ("AC") (right bar) at 48 hrs after stimulation with BD Matrigel 1 M .
• Figure 2 shows the expression levels (by PGR analysis) of the
• TNFRSF-19 gene in AD and AC subjects stimulated by BD MatrigelTM for 48 hours or absent of stimulation by BD MatrigelTM.
• Figure 3 shows the expression levels (by PGR analysis) of the
• TNFRSF-19 gene in AD and AC subjects stimulated by BD Matrigel t M for 48 hours.
• Figure 4 shows tissue specific expressions of the TNFRSF-19 gene in normal and cancer cells
• the present disclosure is directed to methods of diagnosing a neurodegenerative condition, e.g., Alzheimer's disease, comprising contacting a cell sample from a subject with at least one stimulus, such as a protein and/or
• Methods may further comprise comparing the expression of the at least one gene in the cell sample to the expression of the same at least one gene in control cells; and determining whether the subject has the neurodegenerative condition (Alzheimer's disease), wherein a change in the expression of the at least one gene in the cell sample compared to the expression of the same at least one gene in the control cells indicates that the subject has the neurodegenerative condition (Alzheimer's disease).
• neurodegenerative condition refers to a condition resulting in the progressive loss of structure or function of neurons, including the death of neurons.
• Conditions may include, but are not limited to, syndromes of progressive dementia such as Alzheimer's disease. Lewy body dementia, amyotrophy;
• syndromes of disordered posture and movement such as Parkinson's disease, multiple symptom atrophy, tourette syndrome; syndromes of progressive ataxia, such as cerebral cortical ataxias; syndromes of slowly developing muscular weakness or atrophy such as amyotrophic lateral sclerosis (ALS); and aging.
• Parkinson's disease multiple symptom atrophy
• Tourette syndrome syndromes of progressive ataxia, such as cerebral cortical ataxias
• syndromes of slowly developing muscular weakness or atrophy such as amyotrophic lateral sclerosis (ALS); and aging.
• ALS amyotrophic lateral sclerosis
• AD Alzheimer's Disease
• AD refers to any condition where ⁇ and/or neurofibrillary tangles eventually accumulates in the cells of the central nervous system, which accumulation cannot be attributed to other disease or conditions such as CAA.
• AD may be heritable in a Familial manifestation, or may be Sporadic.
• AD includes Familial, Sporadic, as well as intermediates and subgroups thereof based on phenotypic manifestations. In addition, this term includes the development of ⁇ in subjects having Down's Syndrome.
• Sporadic AD refers to AD that develops later in life, usually after the age of about 65, and is not associated with a family history of AD or a mutation in a gene identified as being a risk factor for AD.
• Young-onset refers to AD that occurs in a person under age about 65. Young-onset includes but is not limited to Familial AD.
• Familial AD refers to AD associated with inherited mutations in the presenilin-l gene (PSEN-I), presenilin-2 gene (PSEN-2); the gene encoding Amyloid beta precursor protein (APP), and/or the gene encoding apolipoprotein E (APOE).
• PSEN-I presenilin-l gene
• PSEN-2 presenilin-2 gene
• APP Amyloid beta precursor protein
• APOE apolipoprotein E
• Early-stage AD refers to the stage of AD associated with moderate symptoms of cognitive decline such as memory loss or confusion. Memory loss or other cognitive deficits are noticeable, yet the person can compensate for them and continue to function independently. This stage correlates with Stage 4 of the
• MCI Mild Cognitive Impairment
• the term "subject” means a mamma!, in one
• the subject is a human.
• AD neurodegenerative condition
• Peripheral tissue refers to a tissue that is not derived from
• neuroectoderm and specifically includes olfactory epithelium, tongue, skin (including dermis and/or epidermis), and mucosal layers of the body.
• the term "differentially expressed” or “differential expression” as used herein refers to a measurement of a cellular constituent varies in two samples, a control sample and a test sample. The cellular constituent can be either upreguiated in the experiment relative to the control or downregulated in the experiment relative to the control sample.
• the phrase "detecting the level of expression” includes methods that quantitate expression levels as well as methods thai determine whether a gene of interest is expressed at all.
• the detection can be qualitative or quantitative.
• the differential expression is statistically significant.
• upregulating means detecting an increased the amount or activity of a gene or gene product relative to a baseline or control state, through any mechanism including, but not limited to increased transcription, translation, and/or increased stability of the transcript or protein product Increased expression in a test cell includes a situation where the
• downstream regulating refers to detecting a decrease in the amount or activity of a gene or gene product relative to a baseline or control state, through any mechanism including, but not limited to decreased transcription, translation, and/or decreased stability of the transcript or protein product.
• Decreased expression in a test cell includes a situation where the corresponding gene in a control cell is either unchanged by stimulation or is upreguiated in response to the stimulation.
• a "change in gene expression” refers to detection of upregulation or downregulation.
• microarray or “nucleic acid microarray” refers to a substrate- bound collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable.
• the substrate can be solid or porous, pianar or non-planar, unitary or distributed.
• Microarrays or nucleic acid microarrays include ail the devices so called in Schena (ed.), DMA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); Nature Genet. 21 (1)(suppL):1 -60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000).
• microarrays include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, inter alia, in Brenner et a!., Proc. Natl. Acad. Sci. USA 2000; 97 ⁇ 4):1665-1670.
• the terms “about” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typical, exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Alternatively, and particularly in biological systems, the terms “about” and “approximately” may mean va!ues that are within an order of magnitude, preferably within 5-fold and more preferably within 2-fo!d of a given value. Numerical quantities given herein are approximaie unless stated otherwise, meaning that the term “about” or “approximately” can be inferred when not expressly stated.
• the disclosure provides a method of diagnosing a neurodegenerative condition such as AD by detecting differences in the expression levels of genes in cells from a subject suspected of developing or having the neurodegenerative condition (AD) in response to stimulation with at least one stimulus ("a ceil sample”), compared to expression of the same genes in normal control cells ("control cells") following stimulation with the same stimulus, in one embodiment, the control cells are derived age-matched control subjects and are stimulated with the same stimulus as the cell sample.
• a ceil sample at least one stimulus
• control cells normal control cells
• increased gene expression in the stimulated cell sample compared to the stimulated control cells indicates the presence of the neurodegenerative condition (AD).
• decreased gene expression in the stimulated cell sample compared to the stimulated control cells indicates the presence of the neurodegenerative condition (AD).
• absence of increased gene expression in the stimulated cell sample compared to the stimulated control cells indicates the presence of the neurodegenerative condition (AD).
• absence of decreased expression in the stimulated cell sample compared to the stimulated control cells indicates the presence of the neurodegenerative condition (AD).
• the present disclosure provides a method for diagnosing early-stage AD by detecting the differential changes in gene expression.
• the method as disclosed herein can be used to distinguish Alzheimer's pathology or dementia from that associated with other forms of dementia, such as frontotemporal degenerative dementias (e.g., Pick's disease, corticobasal ganglionic degenerations, and frontotemporal dementia), Huntington's disease, Creutzfeldt Jakob disease, Parkinson's disease, cerebrovascular disease, head trauma, and substance abuse.
• frontotemporal degenerative dementias e.g., Pick's disease, corticobasal ganglionic degenerations, and frontotemporal dementia
• Huntington's disease Creutzfeldt Jakob disease
• Parkinson's disease cerebrovascular disease
• head trauma e.g., Alzheimer's pathology
• substance abuse e.g., Alzheimer's pathology or dementia
• the disclosure provides a method of evaluating disease progression by applying the methods to two or more samples from the same patient taken on separate occasions.
• This embodiment can also be used to evaluate the effect of any AD treatment administered after the first sample is taken but before the send sample is taken.
• AD treatments include Namenda® (memantine), AricepKD (donapazil) and Razadyne® (ga!antamine), an Exelon® (rivastigmine).
• the present disclosure further provides a method of screening therapeutic substances for the treatment or prevention of AD by evaluating the effects of a test agent on the differential expression of genes according to the methods described herein.
• kits to carry out the diagnostic method as disclosed herein Table 1 provides the GenBank accession number for the genes identified to be up-regulated in the AD cells compared with the contro! cells.
• Table 2 provides the GenBank accession number for the genes identified to be downreguiated in the AD cells compared with the control cells.
• TNFRSF-19 or TNF -19 receptor gene is shown herein to be upregulated in AD cells upon stimulation by BD Matrige!TM.
• TNFRSF-19 also known as TROY, TAJ, or TRADE
• TROY TAJ
• TRADE TRADE
• TNF famiiy orphan receptor that is expressed in neurons and involved in axon growth, It is a putative membrane-bound protein of 348 ammo acids with an extracellular domain and an extended cytoplasmic domain.
• the gene symbol report of TNFR5F19 is listed in Table 4,
• TNFRSF-19 is associated with JNK cascade, apoptosis, regulation of I- kappaB kinase/NF-kappaB cascade tumor necrosis factor-mediated signaling pathway. Unlike other TNF receptors, TNFRSF-19 does not appear to play a role in immune response pathways. Thus far, there have been no reports in the literature regarding the relationship between TNFRSF-19 upregulation and AD, demonstrating the potential of the stimulus-elicited genome-wide expression approach to identify new cellular pathways involved in AD.
• the diagnostic method as disclosed herein comprises detecting differential expression in the control sample and the cell sample of at least one gene listed in Table 1 and/or Table 2.
• the diagnostic method as disclosed herein comprises detecting differential expression in the control sample and the cell sample of at least two genes listed in Table 1 and/or Table 2,
• the diagnostic method as disclosed herein comprises detecting differential expression in the control sample and the cell sample of at least five genes listed in Table 1 and/or Table 2.
• the diagnostic method as disclosed herein comprises detecting differential expression in the control sample and the cell sample of at least ten genes listed in Table 1 and/or Table 2. [042] Sn another embodiment, the diagnostic method as disclosed herein comprises detecting differential expression in the control sample and the cell sample of at least fifteen genes listed in Table 1 and/or Table 2,
• the present disclosure provides methods for the diagnosis of a neurodegenerative condition such as Alzheimer's disease using cells from subjects suspected of at risk for developing the neurodegenerative condition (e.g., AD or suspected of having AD), in the methods as disclosed herein, the ceils that are taken from the subject include any viable cells.
• the cells are from peripheral tissues, i.e., non-neurai tissue.
• the tissue is from skin, biood, mucosa, or cerebrospinal fluid.
• the cells are fibroblasts, epithethial cells, endothelial cells, or hematopoietic cells including lymphocytes.
• the ceils are skin epithelial cells, skin fibroblast cells, blood cells or buccal mucosa cells. The ceils may be fresh, cultured, or frozen prior to analysis.
• a punch skin biopsy can be used to obtain skin fibroblasts from a subject. Skin fibroblast samples may also be obtained from a subject by using a surgicai blade. These fibroblasts are analyzed directly or introduced into cell culture conditions.
• the cells are isolated from excised cells using laser capture microdissection to obtain a homogenous population of cells of the same type.
• the at least one stimulus as disclosed herein is chosen from a protein mixture, a polysaccharide mixture, a protein kinase C (PKC) activator, an ⁇ oligomer (ASPD), an agent, and combinations thereof.
• the at least one stimulus comprises two or more stimuli, wherein the two or more stimuli are contacted with the ceil sample simultaneously or
• the at least one stimulus comprises a protein and/or polysaccharide mixture, such as a gelatinous protein and/or polysaccharide mixture.
• stimulation can be induced by cuituring the AD cells, AC ceils, or non-ADD ceils in the protein and/or polysaccharide mixture that induces AD-specific differential gene expression,
• the protein and/or polysaccharide mixture is chosen from laminin, collagen, entactin, heparin sulfate proteoglycan,
• the protein and/or polysaccharide mixture comprises at least one basement membrane protein.
• the protein and/or polysaccharide mixture comprises a preparation, in some embodiments, the preparation is soiubifized. !n at least one embodiment, the preparation is extracted f om tumor or cancer cells, such as the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, and is rich in extracellular matrix (ECM) proteins.
• EHS Engelbreth-Holm-Swarm
• Such preparations may, for example, comprise at least one of laminin, coliagen IV, heparan sulfate proteoglycans, and entaciin/nidogen.
• BD MatrigeiTM which is the trade name (BD Biosciences) for a gelatinous protein mixture secreted by EHS mouse sarcoma cells.
• BD atrigelTM the components of BD atrigelTM are listed in Table 3. This mixture resembles the complex extracellular environment found in many tissues, and may be used as a substrate for ceil culture, BD a ⁇ rigel s M comprises laminin, collagen IV, heparan sulfate proteoglycans, and entactin 1 .
• BD MatrigeiTM polymerizes to produce bioiogicaliy active matrix material resembling the mammalian cellular basement membrane.
• the preparation further comprises TGF-beta, epidermal growth factor, insulin-like growth factor, fibroblast growth factor, tissue plasminogen activator, and/or other growth factors that may or may not occur naturally in a tumor.
• TGF-beta, epidermal growth factor, insulin-like growth factor, fibroblast growth factor, tissue plasminogen activator, and/or other growth factors occur naturally in a tumor, such as the EHS mouse sarcoma tumor.
• BD MatrigeiTM Matrix Growth Factor Reduced (GFR) may be suitable for applications requiring a more highly defined basement membrane preparation of the gel substrate.
• the at least one stimulus is a more defined basement membrane preparation than BD MatrigeiTM Matrix Growth Factor Reduced.
• the preparation may comprise an ECM protein preparation effective for the attachment and differentiation of both normal and transformed anchorage dependent epithelial and other cell types.
• Exemplary cell types include, but are not limited to, neurons, hepatocytes, Sertoli cells, chick lens, and vascular endothelial cells.
• the EGM protein preparation may influence gene expression in adult rat hepatocytes as well as three-dimensional culture in mouse and human mammary epithelial ceils.
• the preparation may, for example, serve as the basis for tumor cell invasion assays, support in vivo peripheral nerve regeneration, and/or provide a substrate for the study of angiogenesis both in vitro and in vivo.
• the ECM protein may also support in vivo propagation of human tumors in immunosupressed mice.
• a volume of chilled ECM protein is dispensed onto tissue culture labware.
• the term “chilled” refers to a temperature less than room temperature, for examp!e, less than about 15°C, less than about 10°C, less than about 5°C, e.g., a temperature of about 4°C.
• the ECM proteins When incubated at an elevated temperature, the ECM proteins may self- assemble to produce a thin film that covers the surface of the iabware,
• the term "elevated” refers to a temperature above room temperature, such as above about 20°C, above about 25 C, above about 30°C, above about 35°C, e.g., a temperature of about 37°C, which is approximately the average temperature of the human body.
• greater volumes of ECM proteins are used to produce thick three-dimensional gels for culturing cells.
• thick gels may be useful in inducing cells to migrate from the surface to the interior of the gel. In some embodiments, this migratory behavior can serve as a model for tumor ceil metastasis.
• the culture medium comprises a layer with a thickness between about 1.0 mm and about 2.0 mm, such as about 1.5 mm or about
• the amount of culture medium may also be expressed as the volume (V) in a well plate according to the relationship V - ( ⁇ , wherein h is the thickness of the layer and r is the radius.
• the volume of culture medium may range from about 400 ⁇ to about 800 ⁇ , such as about 700 ⁇ , with r -
• the at least one stimulus as disclosed herein comprises a protein kinase C (PKC) activator.
• PKC activators are known in the art and include, but are not limited to, bradykinin, phorbol esters such as phorbol 12- myristate 13-acetate (PMA), phorbol 12, 13-dibutyrate (PDBu), phorbol 12, 13- didecanoate (PDD), bombesin, cholecystokinin, thrombin, prostaglandin F2u and vasopressin.
• PKC activators include natural and unnatural diacyiglycerols (DAG), including diacyiglycerols with various fatty acids in the ,2-sn configuration are active.
• DAG contains an unsaturated fatty acid.
• the PKC activator is a macrocyclic lactone, including but is not limited to those in bryostatin compound class and neristatin compound class.
• the PKC activator is a benzoiactam.
• the PKC activator is a pyrrolidine.
• the macrocyclic lactone is bryostatin.
• the bryostatin is bryostafin-1 , - 2, -3, -4, -5, -6, -7, -8, -9, -10, -1 1 , -12, -13, -14, -15, -16, -17, or - 18.
• the at least one stimulus as disclosed herein comprises analogs of bryostatin.
• Analogs of bryostatin commonly referred to as bryologs. are one particular class of PKC activators that are suitable for use in the methods of the present invention. Bryologs are structurally similar, but vary greatly in their affinity for PKC (from 0.25 nM to 10 uM), Whiie bryostatin-1 has two pyran rings and one 6-membered cyclic acetal, in most bryologs one of the pyrans of bryostatin- 1 is replaced with a second 6-membered acetai ring.
• bryologs reduces the stability of bryologs, relative to bryostatin- , for example, in both strong acid or base, but has little significance at physiological pH.
• Bryologs also have a lower molecular weight (ranging from about 600 to 755), as compared to bryostatin-1 (988), a property which facilitates transport across the blood-brain barrier.
• bryologs are described, for example, in U.S. Application No. 1 1/802,723, published as US 2008-0058398A1 .
• PKC activators are polyunsaturated fatty acids (“PUFAs"). These compounds are essential components of the nervous system and have numerous health benefits. In genera!, PUFAs increase membrane fluidity, rapidly oxidize to highly bioactive products, produce a variety of inflammatory and hormonal effects, and are rapidly degraded and metabolized. The inflammatory effects and rapid metabolism is likely the result of their active carbon-carbon double bonds. These compounds may be potent activators of PKC, most likely by binding the PS site.
• PUFAs polyunsaturated fatty acids
• the PUFA is chosen from finoie c acid (shown below).
• PKC activators are PUFA and UFA derivatives,, and cyclopropanated derivatives in particular.
• Certain cyciopropanated PUFAs such as DCPLA (i.e., iinoleic acid with cyclopropane at both double bonds), may be able to selectively activate PKC- ⁇ . See Journal of Biological Chemistry, 2009, 284(50): 34514-34521 ; see also U.S. Patent Application Publication No. 2010/0022645 A1 .
• PUFA derivatives are thought to activate PKC by binding to the PS site.
• Cyclopropanated fatty acids exhibit low toxicity and are readily imported into the brain where they exhibit a long half-life (t1 ⁇ 2). Conversion of the double bonds into cyclopropane rings prevents oxidation and metabolism to inflammatory byproducts and creates a more rigid U-shaped 3D structure that may result in greater PKC activation. Moreover, this U-shape may result in greater isoform specificity. For example, cyclopropanated fatty acids may exhibit potent and selective activation of PKC- ⁇ ,
• PKC-activating fatty acids are Omega-3 PUFA
• the Omega-3 PUFA derivatives are chosen from cyclopropanated docosahexaenoic acid, cyclopropanated eicosapeniaenosc acid, cyciopropanated rume!enic acid, cyclopropanated parinaric acid, and
• Omega-6 PUFA derivatives are chosen from cyciopropanated linoieic acid ("DCPLA,” CP2 form shown below),
• cyclopropanated dihomo-gamma-iinotenic acid cyclopropanated docosadsenoic acid, cyciopropanated adrenic acid, cyclopropanated caiendic acid, cyclopropanated docosapentaenoic acid, cyclopropanated jacaric acid, cyciopropanated pinoienic acid, cyclopropanated podocarpic acid, cyclopropanated tetracosatetranoic acid, and cyciopropanated tetracosapentaenoic acid.
• Vemolic acid is a naturally occurring compound. However, it is an epoxy! derivative of linoieic acid and therefore, as used herein, is considered an Omega-6 PUFA derivative. In addition to vernolic acid, cyclopropanated vernolic acid (shown below) is an Omega-6 PUFA derivative.
• Omega-9 PUFA derivatives are chosen from cyclopropanated eicosenoic acid, cyclopropanated mead acid, cyclopropanated erucic acid, and cydopropanated nervonic acid.
• UFA monounsaturated fatty acid
• the UFA derivatives are chosen from cyclopropanated oleic acid (shown below), and cyclopropanated eiaidic acid (shown below).
• PKC-activating MUFA derivatives include epoxylated compounds such as trans-9,10-epoxystearic acid (shown below).
• Omega-5 and Omega-7 PUFA derivatives are Omega-5 and Omega-7 PUFA derivatives.
• cyclopropanated rumenic acid cyclopropanated afphaelostearic acid
• cyclopropanated catalpic acid cyclopropanaied punscic acid
• PKC activators are fatty acid alcohols and derivatives thereof, such as cyclopropanaied PUFA and MUFA fatty alcohols. It is thought that these aicoho!s activate PKC by binding to the PS site. These alcohols can be derived from different classes of fatty acids.
• the PKC-activating fatty alcohols are derived from Omega-3 PUFAs, Omega-6 PUFAs, Omega-9 PUFAs, and MUFAs, especially the fatty acids noted above.
• the fatty alcohol is chosen from cyclopropanated linolenyl alcohol (CPS form shown below),
• PKC activators are fatty acid esters and derivatives thereof, such as cyclopropanaied PUFA and MUFA fatty esters.
• the cyclopropanaied fatty esters are derived from Omega-3 PUFAs, Omega-6 PUFAs, Omega-9 PUFAs, MUFAs, Omega-5 PUFAs, and Omega-7 PUFAs. These compounds are thought to activate PKC through binding on the PS site.
• One advantage of such esters is that they are generally considered to be more stable that their free acid counterparts.
• the PKC-activating fatty acid esters derived from Omega-3 PUFAs are chosen from cyciopropanated eicosapentaenoic acid methyl ester (CPS form shown below)
• the Omega-3 PUFA esters are chosen from esters of DHA-CP6 and aliphatic and aromatic alcohols, in one embodiment, the ester is cyciopropanated docosahexaenoic acid methyl ester (CP8 form shown below).
• DHA CP6 in fact, has been shown to be effective at a concentration of 10 nM. See, e.g., U.S Patent Application Publication No. 2010/0022845.
• PKC-activating fatty esters derived from Omega-8 PUFAs are chosen from cyciopropanated arachidonic acid methyl ester (CP4 form shown below),
• esters are derivatives of DCPLA (CP6-linoieic acid),
• the ester of DCPLA is an aikyi ester.
• the aikyi group in one embodiment, may be chosen from methyl, ethyl, propyl (e.g., isopropyl), and butyl (e.g., tert-butyS) esters.
• the esters of DCPLA are derived from a benzyl alcohol (unsubstituted benzyl alcohol ester shown below), in yet another embodiment
• the esters of DCPLA are derived from aromatic alcohols such as phenols used as antioxidants and natural phenols with pro-learning ability. Some specific examples include estradiol, butylated hydroxytoluene, resveratrol,
• PKC activators is fatty esters derived from
• the cyclopropanated MUFA ester is chosen from cyclopropanated elaidic acid methyl ester (shown below), and cyclopropanated oleic acid methyl ester (shown below) >
• PKC activators are sulfates and phosphates derived from PUFAs, MUFAs, and their derivatives.
• the sulfate is chosen from DCPLA sulfate and DHA sulfate (CP6 form shown below).
• the phosphate is chosen from DCPLA phosphate and DHA phosphate (CP6 form shown below).
• the at least one stimulus as disclosed herein comprises oligomeric ⁇ (amylosheriods, ASPDs).
• oligomeric ⁇ can have a molecular weight of >100 kDa. These oligomers were reported to be highly toxic and had similarities to those found in the AD brain (Nouguchi et a!., 2009).
• the at least one stimulus as disclosed herein comprises an agent.
• the agent includes, but is not limited to, bradykinin, insulin, phobo! esters, lysophosphatidylcholine, lipopo!ysaccharide, anthracyc!ine tendorubicin, and vanadyl sulfate.
• Gene expression can be measured by both low-throughput methods such as Northern Blotting, in situ hybridization, reverse transcription quantitative polymerase chain reaction (RVQPCR), and real time PGR, and high-throughput methods such as microarrays and SAGE to detect differentia! gene expression. ⁇ n one embodiment, detection is conducted using automatic, computerized equipment in a high-throughput setting, such as microarray technology.
• low-throughput methods such as Northern Blotting, in situ hybridization, reverse transcription quantitative polymerase chain reaction (RVQPCR), and real time PGR
• high-throughput methods such as microarrays and SAGE to detect differentia! gene expression.
• detection is conducted using automatic, computerized equipment in a high-throughput setting, such as microarray technology.
• the method of the present disclosure provides detecting the gene transcript such as mRNA, including microRNA, cDNA or cRNA.
• the transcript can be from both coding and non-coding regions of the gene.
• the transcript can be detected in situ in the cell or in purified form extracted from the cell.
• the nucleic acid is isolated and purified from the cell and then used in the gene expression assay.
• the method of the present disclosure provides detecting the protein product, or portion thereof, expressed from a gene transcript.
• Protein-based assays include low-throughput methods such as Western blotting and ELISA, and high throughput protein microarrays.
• the method of the present disclosure further comprises detecting the activity or activation state of the detected protein product, such as the phosphorylation of given protein.
• gene transcripts e.g., cDNAs
• a microarray one which is the test ceil that has been stimulated with at least one stimulus and another the control cell, preferably of the same cell type, which has been stimulated with at least one stimulus, preferably the same stimulus.
• the nucleic acid derived from each of the two cell types are differently labeled so that they can be
• microarrays to evaluate differentially expressed transcripts is well known. See, e.g., U.S. 6,973.388. This technique typically involves preparing or purchasing microarrays containing known cDNA transcripts, extracting and labeling RNA from test cells, hybridizing the test RNA to the array, detecting and visualizing signal, performing statistical analysis on the results, and, optionally, validating the microarray results using low-throughput techniques.
• Pre-made cDNA microarrays are commercially available from e.g., Affymetrix® (Santa Clara, CA), Agilent Technologies® (Santa Clara, CA) and AlphaGene ⁇ (Woburn, MA). These include whole genome arrays and targeted subsets of known genes.
• differential expression of genes is detected using serial analysis of gene expression (SAGE), SAGE quantitatively determines the amount of times a small portion of a specific mRNA transcript is expressed (a tag).
• SAGE serial analysis of gene expression
• the output of SAGE is a list of short sequence tags and the number of times it is observed.
• SAGE serial analysis of gene expression
• the cell sample demonstrates an observable difference in the level of expression of one or more genes compared with the level of expression of the same gene or genes in the control ceils.
• the differential expression is quantitative.
• the level of gene expression detected in the test DCis is about 1-fold, 2-fold, 5-foid, 10-fold, and 100- fold upreguiated or downregulated compared to the control cells.
• expression levels of the genes can be measured at about 1 hour, about 1 ,5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 5 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 38 hours, about 48 hours, about 60 hours, or even about 72 hours or more after culturing.
• Figure 1 shows the expression level (Microarray data) of tumor necrosis factor receptor superfamily, member 19 (TNFRSF-19) gene in fibroblast cells from subjects with AD (left bar) and in fibroblast ceils age-averaged controi subjects ("AC”) (right bar) at 48 hrs after stimulation with BD atrigelTM
• this disclosure relates to methods of screening therapeutic substances for the treatment or prevention of the neurodegenerative condition (AD) using the diagnostic tests described herein.
• AD neurodegenerative condition
• compounds which reverse or improve the observed differences in gene expression described herein would be identified and selected as a substance potentially useful for the treatment or prevention of the neurodegenerative condition (AD).
• the screening method comprises the steps of contacting cells from a subject that has been diagnosed with AD with a test compound for a period of time, followed by contacting the cells with at least one stimulus as disclosed herein, and determining whether the test compound alters the differential expression of the genes identified according to the methods of the present disclosure towards levels observed in controi cells from normai subjects.
• the ceils contacted with the test compound are derived from a subject diagnosed with the neurodegenerative condition (AD) according to the methods of the present disclosure.
• kits comprising products useful for carrying out the diagnostic methods as disclosed herein.
• the kits may also include instruments, buffers and storage containers necessary to perform one or more biopsies, such as punch sk n biopsies.
• the kits can include high-density
• kits may also contain instructions relating to the identification of differentially expressed genes used for the neurodegenerative condition (AD) diagnosis.
• AD neurodegenerative condition
• kits may contain a single diagnostic test or any combination of the tests described herein.
• AH of the differences disclosed herein between control and the neurodegenerative condition (AD) ceils form the basis for the clinical tests and diagnostic kits for the neurodegenerative condition (AD) diagnosis, as well as the methods of screening compounds for treatment or prevention of the neurodegenerative condition (AD) disclosed herein.
• the diagnostic methods as disclosed herein may be used in combination with any other diagnostic methods.
• Exemplary methods include physical and neurological evaluation; biomarker detection; and structural (MRI, CT) and functional brain imaging (PET; FDG-PET).
• MRI, CT structural
• PET functional brain imaging
• FDG-PET functional brain imaging
• the methods of the present disclosure can be used in combination with evaluating mutations in the genes known to be involved in Familial AD, Additional methods of diagnosing AD are described in U.S. patent 6,080,582 and 6,300,085 to Alkon et al.
• WO2007/047029 to Aikon et ai. directed to diagnosing AD in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins (Erkl/Erk 2) in cells after stimulation with a PKC activator. See also, Zhao et a!., Neurobiol. Dis. 2002 Oct; 1 1 (I): 166-83.
• FIG. 1 shows the expression level (Microarray data) of tumor necrosis factor receptor superfamiiy, member 19 (TNFRSF-19) gene in fibroblast cells from subjects with AD (left bar) and in fibroblast cells age-averaged control subjects ("AC") (right bar) at 48 hrs after stimulation with BD MatrigelTM.
• TNFRSF-19 tumor necrosis factor receptor superfamiiy, member 19
• AC age-averaged control subjects
• Figure 2 shows the expression levels (by PGR analysis) of the
• TNFRSF-19 gene in AD and AC subjects stimulated by BD MatrigelTM for 48 hours or absent of stimulation by BD MatrigelTM.
• the data was normalized by 3 age- matched controls for each group.
• the bars denoted by AC1 through AC6 and the bars denoted by AD1 through AD8 represent data obtained from non-freshly taken cells from the AC subjects or AD subjects.
• the bars denoted by 0025 M39 AC, 0019 M33 AC, 0055 M55 AC, and 0065 M69 AD represent data obtained from freshly taken biopsy fibroblast cells.
• Figure 3 shows the expression levels (by PGR analysis) of the
• TNFRSF-19 gene in AD and AC subjects stimulated by BD MatrigelTM for 48 hours.
• the data was normalized by normalized by each gel by PGR.
• the bars denoted by AC1 through AC6 and the bars denoted by AD1 through AD6 represent data obtained from non-freshly taken cells from the AC subjects or AD subjects.
• the bars denoted by 0025 M39 AC, 0019 M33 AC, 0055 M55 AC, and 0085 69 AD represent data obtained from freshly taken biopsy fibroblast cells.
• Figure 4 shows tissue specific expressions of the TNFRSF-19 gene in normal and cancer cells.
• BD MatrigelTM basement membrane preparation The BD Matrigel Matrix Growth Factor Reduced (BD Biosciences) was be thawed at 4°C on ice 30 min. before use. All pipettes, tips, and 12 well culture plates were be pre-cooled to 4°C before use. The BD MatrigelTM Matrix Growth Factor Reduced was mixed to homogeneity using cooled pipettes. No solid aggregates of the gel should be included within the mixture. 12 well culture plates were kept on ice for 30 min.
• BD Cell Recovery Solution (BD Biosciences) was used to recover ceils from BD MatrigelTM Matrix. First the cell culture medium was removed and washed the layer of cells on the BD Matrige! , M matrix three times with cold PBS. 2 mL of the recovery solution was per 35 mm dish. The cellular aggregates/gel layer was scraped into an ice-cold 50 ml conical tube sitting on ice. To recover all material from the dish was rinsed one time with 2mL of BD Cell Recovery Solution and was transferred to the tube.
• the BD Matrige was completely dissolved by rocking the tube several time back and forth and kept on ice for 1 hour or until the BD MatrigelTM has complete dissolved. After about 30 minutes on ice, the cells were settled to the bottom of the tube indicating that the gei has been dissolved. The cellular
• RNA quality and integrity were determined utilizing an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, OA, USA) and absorbance at A260/A280. Only high quality RNA, having a RIN of >7.0, and an A260/280 absorbance ratio of >1 .8, was utilized for further experimentation. RNA was converted to doubie-stranded cDNA and amplified using in vitro transcription that included amino-aiiyi UTP, and the aRNA product was subsequently conjugated with Cy5TM NHS ester ⁇ GEH
• Fragmented aRNA was hybridized at 50 °C overnight using the HybBag mixing system with 1 X OneArray Hybridization Buffer (Pha!anx Biotech), 0.01 mg/ml sheared salmon sperm DNA (Promega, Madison, Wl, USA), at a .
• lymphocytes and microglial Harris-White, et monocytes, activation, and al., (2Q04), J. neutrophils and neuronal apoptosis.
• Neurosci. Res. fibroblasts. Increase low density 77: 217- 228. Induce lipoprotein receptor- angiogenesis. related protein
• FGF FGF treatment APP regulates Be!lucci et ai., modulates ECM EGF receptor (2007). Mol. molecule production expression Med. 13: 542- and gene 550.
• PDGF Platelet-derived PDGF regulates the Gianni et ai., growth factor ⁇ -, ⁇ -secretase- (2004), J. Bio.
• IGF IGF signaling IGF protects cells Niikura, T,. J.
• Transferrin Transferrin gene Lower brain Fisher et ai. s polymorphism in AD, transferrin ievels in (1997), Life and dementia with AD Science 60: Levvy bodies 227-227, 1997.
• Amylase 3-Muscarinic Sramek et aL agonist activity in AD (1995), Prog.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Analytical Chemistry (AREA)
• Molecular Biology (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Physics & Mathematics (AREA)
• Microbiology (AREA)
• Pathology (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Biophysics (AREA)
• General Engineering & Computer Science (AREA)
• Tropical Medicine & Parasitology (AREA)
• Cell Biology (AREA)
• Toxicology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47116384

Family Applications (1)

Country Status (5)

Cited By (3)

Families Citing this family (3)

Citations (10)

Family Cites Families (1)

• 2012
  • 2012-10-05 CA CA2861668A patent/CA2861668C/en active Active
  • 2012-10-05 US US14/346,822 patent/US20140235496A1/en active Pending
  • 2012-10-05 WO PCT/US2012/059137 patent/WO2013052922A1/en not_active Ceased
  • 2012-10-05 JP JP2014534811A patent/JP2014528247A/ja active Pending
  • 2012-10-05 EP EP12780586.9A patent/EP2764120B1/en active Active
• 2017
  • 2017-10-05 JP JP2017195118A patent/JP6636488B2/ja active Active

Patent Citations (11)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events